AI Reads Chest Scans to Predict Lung Cancer Type When Brain Metastases Strike First

When lung cancer announces itself with tumors already spreading to the brain, every day of waiting matters. The optimal treatment for those brain metastases depends critically on which type of lung cancer a patient has, yet the biopsies, pathology processing, and molecular testing needed to determine that subtype can take days to weeks. A new proof-of-concept study published in the Journal of Neuro-Oncology suggests that machine-learning models built from ordinary clinical data and chest CT reports could give clinicians a probabilistic head start, estimating whether a patient has small cell lung cancer, EGFR-mutated non-small cell lung cancer, or EGFR-wild-type non-small cell lung cancer before definitive testing returns. The work, led by researchers at the University of California Irvine, is not a replacement for tissue diagnosis, but it points toward a future where the information already sitting in a hospital record can be harnessed to guide urgent, high-stakes decisions.

The clinical logic behind the study is straightforward but consequential. Small cell lung cancer is exquisitely radiosensitive, so outside true emergencies patients with this subtype may derive limited benefit from surgical resection of brain metastases. Large tumors from non-small cell lung cancer, by contrast, may warrant surgical removal before radiotherapy to relieve mass effect and improve local control. And a subset of non-small cell lung cancers harboring EGFR driver mutations may allow clinicians to defer upfront radiation entirely while trializing a tyrosine kinase inhibitor with intracranial activity. Three subtypes, three fundamentally different treatment pathways, and a diagnostic pipeline too slow to inform the moment when those pathways are chosen. The researchers therefore set out to build a tool that could estimate subtype using data available on day one.

The study team retrospectively identified 305 patients with metastatic lung cancer diagnosed between 2016 and 2025 at a single institution. In an unusual and methodologically deliberate design choice, the 182 patients who did not have brain metastases at diagnosis formed the training cohort, while the entire 123-patient group presenting with synchronous brain metastases was reserved as a held-out testing cohort. This partitioning preserved the clinically relevant target population for honest evaluation, though it introduced the possibility of distribution shift between the two groups, a concern the investigators addressed with dedicated sensitivity analyses. Patients were classified into three groups: small cell lung cancer, EGFR-mutated NSCLC, and EGFR-wild-type NSCLC. EGFR was singled out for independent categorization because it is among the most prevalent driver mutations and, unlike KRAS, has multiple central-nervous-system-penetrating targeted therapies already approved.

Clinical variables included sex, age, race, smoking history, pack-years, and prior lung disease such as emphysema or interstitial lung disease. The imaging features were extracted from narrative diagnostic chest CT reports using a firewalled institutional large language model, Anthropic Claude Sonnet 4.6, blinded to patient identifiers and tumor subtype. The model determined the presence or absence of fifteen predefined features, including tumor location, pleural attachment, cavitation, lymphangitic spread, fibrosis, miliary pattern, emphysema, mediastinal lymphadenopathy, vessel encasement, superior vena cava involvement, and osseous metastases. To validate this extraction, investigators manually reviewed fifty randomly selected reports as a reference standard, finding 96.8 percent overall agreement and a Cohen’s kappa of 0.918 across 750 individual feature comparisons. Notably, the authors emphasize that the modeling approach itself does not depend on the use of a large language model; the tool simply enabled consistent, high-throughput data extraction.

Two machine-learning approaches were tested: LASSO-regularized logistic regression, which performs feature selection while guarding against overfitting, and random forest, an ensemble method that aggregates many decision trees. Each was trained on clinical variables alone and on the combined clinical-plus-imaging feature set, and performance was evaluated with one-versus-rest AUC analysis in the held-out brain metastasis cohort. The combined LASSO logistic regression model achieved testing AUCs of 0.887 for EGFR-mutated disease, 0.811 for small cell lung cancer, and 0.801 for EGFR-wild-type disease. The random forest reached 0.907, 0.783, and 0.810 respectively. Adding imaging features significantly improved discrimination for EGFR-mutated cancer and small cell histology under logistic regression, and for small cell histology under random forest, while clinical variables alone were largely sufficient for the EGFR-wild-type group. Neither modeling approach demonstrated clear superiority over the other.

The three-way classification analysis offered perhaps the most clinically interpretable results. Both multiclass models showed their highest positive predictive value for EGFR-mutated cancer, exceeding 80 percent, with negative predictive values approaching 90 percent. For small cell lung cancer, the pattern inverted: positive predictive value was low, around 33 to 36 percent, but negative predictive value remained high, above 89 percent. In practical terms, the models are better at ruling out small cell histology than at confirming it, and patients predicted to have EGFR-mutated disease may represent a particularly informative group for early multidisciplinary discussion. An exploratory analysis of misclassified EGFR-wild-type patients revealed that several harbored other driver mutations, including KRAS G12A, ERBB2 mutations, and EML4-ALK fusions, suggesting the EGFR-wild-type category may partly capture a broader oncogenic-driver phenotype rather than a homogeneous entity.

Decision curve analysis added a layer of clinical realism by quantifying net benefit across a range of threshold probabilities, representing the minimum confidence at which a clinician would act on a predicted subtype. For EGFR-mutated cancer, the multiclass random forest outperformed both the flag-all and flag-none reference strategies across the entire examined threshold range from 0.05 to 0.80. At a representative threshold of 0.30, the models corresponded to roughly 12 to 14 additional correct EGFR-positive identifications per 100 patients evaluated without an increase in false positives. For small cell lung cancer, benefit was confined to low thresholds below approximately 0.30 and turned negative at higher thresholds, a limitation the authors attribute largely to the small number of small cell cases, just 19 of 123 testing patients, which constrains attainable positive predictive value and widens confidence intervals.

The feature-level analyses revealed biologically plausible signals. Miliary pulmonary metastases and pleural attachment were associated with EGFR-mutated disease, consistent with previously described imaging phenotypes of this molecular subtype, while smoking history, greater pack-years, superior vena cava involvement, and central thoracic disease distribution were associated with small cell histology. Cavitation and pleural attachment leaned toward EGFR-wild-type tumors. The investigators also confronted their design’s weaknesses directly: the single-institution cohort may overrepresent EGFR-mutated disease, imaging features were drawn from unstructured radiology reports rather than standardized interpretation, and the EGFR-wild-type group is biologically heterogeneous. Covariate reweighting and size-matched sensitivity analyses showed minimal change in model discrimination, but the authors stress that these checks cannot prove the training and testing populations were equivalent.

The bottom line is carefully bounded. The researchers explicitly state that these models should not substitute for histologic or molecular diagnosis, nor serve as a stand-alone basis for treatment decisions, and that generalizability requires validation in independent external cohorts. Yet as a proof of concept, the study demonstrates something genuinely useful: clinical and radiographic information already available at initial presentation can carry meaningful probabilistic information about lung cancer subtype during the diagnostic limbo that follows a devastating synchronous brain metastasis diagnosis. In that window, when neurosurgeons, radiation oncologists, and medical oncologists must weigh surgery, radiosurgery, and targeted therapy against one another, even an imperfect early estimate could sharpen multidisciplinary conversations and help prioritize which patients need expedited molecular confirmation. Prospective implementation studies will determine whether that promise translates into better outcomes, but the study makes a compelling case that the answers clinicians need may already be hiding in the charts and scans they see on day one.

Subject of Research: Machine-learning prediction of lung cancer subtype from clinical and chest CT features to guide early management of synchronous brain metastases

Article Title: Predictive modeling of lung cancer subtype with integration of clinical and thoracic imaging features to guide early brain metastasis management

Article References: Park, J., Buclez, P., Lubisich, J., Hanubal, K., Inda, A., Hui, C., Harris, J., & Simon, A. (2026). Predictive modeling of lung cancer subtype with integration of clinical and thoracic imaging features to guide early brain metastasis management. Journal of Neuro-Oncology, 180(1), Article 5. https://doi.org/10.1007/s11060-026-05812-z

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05812-z

Keywords: lung cancer, brain metastases, EGFR mutation, small cell lung cancer, non-small cell lung cancer, machine learning, chest CT, predictive modeling, LASSO logistic regression, random forest, radiology reports, Journal of Neuro-Oncology